CA
NZ
UK
AU
IND
US
• EXoZymes (NASDAQ: EXOZ) receives a $2,028,518 NIH grant to develop rare cannabinoid analogs for drug discovery.
• A decision regarding RP1 for advanced melanoma is expected by August 2, 2026.
• Invitae (NYSE: NVTA) confirms the departure of its chief legal officer as part of a leadership restructuring.
• Facilities receive consistent Medicare payments under current coding.
• A fertility bioscience company filed an 8-K outlining key corporate developments, including an Alabama joint venture.
• The record date for determining eligible shareholders has been established.
The biotech and small-cap space rarely sits still, and this week has served up a concentrated dose of regulatory catalysts, commercial milestones, financing activity, and strategic repositioning across six companies spanning pharma, medical devices, cryptocurrency mining, and digital infrastructure. From a Japanese patent grant …
• The biotech firm has amended its equity incentive plan to increase the share reserve by 3,400,000 shares.
• BridgeBio Pharma (NASDAQ: BBIO) shareholders have approved the addition of 2M shares to the company's equity plan.
• The move is expected to bring fresh perspectives and expertise to the company
Please wait processing your request...